{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T16:11:12Z","timestamp":1791907872982,"version":"4.3.4"},"reference-count":19,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,4,4]],"date-time":"2020-04-04T00:00:00Z","timestamp":1585958400000},"content-version":"vor","delay-in-days":3,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2020,4]]},"DOI":"10.1016\/j.ejps.2019.105200","type":"journal-article","created":{"date-parts":[[2019,12,18]],"date-time":"2019-12-18T22:33:04Z","timestamp":1576708384000},"page":"105200","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":27,"special_numbering":"C","title":["Development and validation of a Level A in-vitro in-vivo correlation for tofacitinib modified-release tablets using extrudable core system osmotic delivery technology"],"prefix":"10.1016","volume":"147","author":[{"suffix":"IV","given":"Joseph","family":"Kushner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manisha","family":"Lamba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Stock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronnie","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary Anne","family":"Nemeth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Alvey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raymond","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"DeMatteo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Blanchard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejps.2019.105200_bib0001","series-title":"Handbook of Pharmaceutical Controlled Release Technology","first-page":"751","article-title":"Osmotic drug delivery from asymmetric membrane film-coated dosage forms","author":"am Ende","year":"2000"},{"key":"10.1016\/j.ejps.2019.105200_bib0002","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1081\/PDT-35915","article-title":"A thermodynamic model for organic and aqueous tablet film coating","volume":"10","author":"am Ende","year":"2005","journal-title":"Pharm. Dev. Technol"},{"key":"10.1016\/j.ejps.2019.105200_bib0003","unstructured":"FDA Center for Drug Evaluation and Research, 2011. Clinical pharmacology and biopharmaceutics review of tofacitinib. NDA203214. Available at:http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2012\/203214Orig1s000ClinPharmR.pdf. Accessed 6\/14\/2016."},{"key":"10.1016\/j.ejps.2019.105200_bib0004","unstructured":"FDA Center for Drug Evaluation and Research, 2015. Clinical pharmacology and biopharmaceutics review of tofacitinib. NDA208246. Available at:https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2016\/208246Orig1s000ClinpharmR.pdf. Accessed 3\/21\/2017."},{"key":"10.1016\/j.ejps.2019.105200_bib0005","series-title":"Guidance For Industry: Extended release Oral Dosage Forms: Development, Evaluation and Application of in Vitro\/In Vivo Correlations","first-page":"1","year":"1997"},{"key":"10.1016\/j.ejps.2019.105200_bib0006","unstructured":"Food and Drug Administration, 1997b. Guidance for industry: SUPAC-MR: modified release solid oral dosage forms. Available at:http:\/\/www.fda.gov\/downloads\/Drugs\/Guidances\/UCM070640.pdf. Accessed 3\/21\/2017."},{"key":"10.1016\/j.ejps.2019.105200_bib0007","series-title":"Guidance for Industry: Statistical Approaches to Establishing Bioequivalence.","first-page":"1","year":"2001"},{"key":"10.1016\/j.ejps.2019.105200_bib0008","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1002\/bdd.1820","article-title":"Analysis of Level A in vitro-in vivo correlations for an extended-release formulation with limited bioavailability","volume":"34","author":"Kakhi","year":"2013","journal-title":"Biopharm. Drug Dispos."},{"key":"10.1016\/j.ejps.2019.105200_bib0009","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1208\/s12248-015-9765-1","article-title":"Applications of in vitro-in vivo correlations in generic drug development: case studies","volume":"17","author":"Kaur","year":"2015","journal-title":"AAPS. J"},{"key":"10.1016\/j.ejps.2019.105200_bib0010","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1208\/s12248-015-9816-7","article-title":"Comparison of deconvolution-based and absorption modeling IVIVC for extended release formulations of a BCS III drug development candidate","volume":"17","author":"Kesisoglou","year":"2015","journal-title":"AAPS J."},{"key":"10.1016\/j.ejps.2019.105200_bib0011","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1002\/jcph.734","article-title":"Extended-release once-daily formulation of tofacitinib: evaluation of pharmacokinetics compared with immediate-release tofacitinib and impact of food","volume":"56","author":"Lamba","year":"2016","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.ejps.2019.105200_bib0012","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.ejpb.2009.07.002","article-title":"Oral osmotically driven systems: 30 years of development and clinical use","volume":"73","author":"Malaterre","year":"2009","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ejps.2019.105200_bib0013","doi-asserted-by":"crossref","first-page":"3412","DOI":"10.1002\/jps.24191","article-title":"A commentary on scale-up of pan coating process using microenvironmental control","volume":"103","author":"Pandey","year":"2014","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejps.2019.105200_bib0014","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1208\/pt0704102","article-title":"Scale-up of a pan-coating process","volume":"7","author":"Pandey","year":"2006","journal-title":"AAPS Pharm. Sci. Tech."},{"key":"10.1016\/j.ejps.2019.105200_bib0015","doi-asserted-by":"crossref","first-page":"2529","DOI":"10.1007\/s11095-014-1349-8","article-title":"In vitro- in vivo correlation's dissolution limits setting","volume":"31","author":"Roudier","year":"2014","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejps.2019.105200_bib0016","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1111\/j.1365-2036.2005.02683.x","article-title":"Intestinal fluid volumes and transit of dosage forms as assessed by magnetic resonance imaging","volume":"22","author":"Schiller","year":"2005","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.ejps.2019.105200_bib0017","series-title":"Oral Controlled Release Formulation Design and Drug Delivery: Theory to Practice","article-title":"Controlled release using bilayer osmotic tablet technology: reducing theory to practice","author":"Shamblin","year":"2010"},{"key":"10.1016\/j.ejps.2019.105200_bib0018","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S0168-3659(01)00550-8","article-title":"Formulation aspects in the development of osmotically controlled oral drug delivery systems","volume":"79","author":"Verma","year":"2002","journal-title":"J. Control Rel."},{"key":"10.1016\/j.ejps.2019.105200_bib0019","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.jconrel.2008.11.017","article-title":"Extrudable core system: development of a single-layer osmotic controlled-release tablet","volume":"134","author":"Waterman","year":"2009","journal-title":"J. Control Rel."}],"container-title":["European Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0928098719304737?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0928098719304737?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T11:50:36Z","timestamp":1760529036000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0928098719304737"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4]]},"references-count":19,"alternative-id":["S0928098719304737"],"URL":"https:\/\/doi.org\/10.1016\/j.ejps.2019.105200","relation":{},"ISSN":["0928-0987"],"issn-type":[{"value":"0928-0987","type":"print"}],"subject":[],"published":{"date-parts":[[2020,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Development and validation of a Level A in-vitro in-vivo correlation for tofacitinib modified-release tablets using extrudable core system osmotic delivery technology","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejps.2019.105200","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"105200"}}